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Poster Session I S253interested in younger versus older patients(pts) for any difference in
disease characteristics and clinical outcome in the era of newer
agents.
Patients: We retrospectively analyzed 122 consecutive pts
(M77:F55) who underwent ASCT for multiple myeloma between
February, 2005 and July 2010, after newer agents were introduced.
Median age was 58 years (38-76). The median length of follow-up
was 1.1 year (33-1833days) after the initial transplant date.
Patient characteristics: High risk cytogenetics was seen in 40%
(n 5 29) of patients younger than 60 years of age compared to
28% (n5 14) of the pts in older group. Either deletion 13 or 17 de-
letion was similar in both groups 20% (n5 15) in younger and 22%
(n5 11) in older group. Trisomy 11 was more commonly seen in the
younger patients 11% (n 5 8) vs. 0%. Prior MGUS or smoldering
myeloma was more common in older pts (16%; n 5 8) vs. (7%;
n 5 5). Plasmacytomas (PCM) as presenting symptom was more
common 24% (n 5 17) in younger patients compared to 16%
(n 5 8) older pts.
Table 1. Patient characteristics of multiple myeloma patients
younger and older than 60 years of age
Age in years <60 (n572) >60 (n550)M:F 44 : 28 29 : 21
Disease prior to myeloma
Light chain disease 0 (0%) 2 (4%)
MGUS/smoldering MM 5 (7%) 8(16%)
Plasmacytoma 17 (24%) 8 (16%)
Amyloid 1 (1%) 3 (6%)
Plasma cell leukemia 0 (0%) 1 (2%)
De novo myeloma 49 (68%) 28 (56%)
WHO/ISS
albumin 3.6 (2.1-4.6) 3.6 (2.0-4.6)
Beta2 microglobulin 2.7 (1.4-34) 3.6 (1.3-15)
I 32 (44%) 12 (24%)
II 14 (19%) 22 (44%)
III 24 (33%) 12 (24%)
Not calculated 2(3%) 4 (8%)
Durie-Salmon staging
I 9 (12%) 9 (18%)
II 14 (19%) 17 (34%)
III 49 (68%) 24 (48%)
Cytogenetic abnormalities
13 del/17 del 15 (20%) 11 (22%)
Trisomy 11 8 (11%) 0 (0%)
T(11:14) 1 (1%) 3 (6%)
complex 5 (7%) 1 (2%)
aneuploidy 0 (0%) 1 (2%)
Pretransplant treatments
VAD/DVD 9 (12%) 9 (18%)
Melphalan 4 (7%) 4 (8%)
Thalidomide 18 (25%) 16 (32%)
Lenalidomide 14 (19%) 9 (18%)
Bortezomib 17 (24%) 12 (24%)
Post transplant treatments
Thalidomide 2 (3%) 2 (4%)
Lenalidomide 37 (51%) 29 (58%)
No maintenance 27 (38%) 18 (36%)
Second transplants 2 (3%) 1 (2%)Methods: Various pretransplant characteristics including cytoge-
netics and free light chain ratios were evaluated for remission status
and impact on progression.
Results: Majority of younger pts (44%; n 5 32) had stage I disease
by ISS staging compared to older pts with stage II disease (44%; n5
22). By Durie-Salmon staging majority had stage III disease; 68% of
younger (n5 49) compared to 48% of older pts (n5 24). The 3 year
overall survival was 71% for pts over 50 years of age compared to
40.2% for pts younger than 50 years of age (p5 0.065).Median sur-
vival was 927 days for patients younger than 50 years of age, but not
reached for pts older than 50 years. Three patterns of relapses were
seen: Bone marrow (BM) relapse; free light chains (FLC); plasmacy-toma only recurrence.None of the pts with FLC only relapse died of
relapse.
Conclusion:The younger patients have more aggressive clinical
presentation compared to older myeloma patients. Pre and post
transplant strategies need to be better defined to improve out-
come of younger myeloma patients with aggressive clinical
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Hematopoietic stem cell transplant (HSCT) remains the pri-
mary therapy for Hodgkin’s Lymphoma (HL) patients who re-
lapse following standard therapies. Those who relapse have
limited options for long-term cure. Two approaches have recently
shown promise: T cell therapy, and therapy with epigenetic-mod-
ifying drugs. As usually seen in cancer, a multimodality approach
may work best: we thus hypothesize that a combined immune–
based and epigenetic therapy, targeting our antigen of choice MA-
GEA4, will be an effective approach for treating relapsed HL post
HSCT.
Success in T cell therapy targeting Epstein Barr virus (EBV) pro-
teins in lymphoma is limited because most are EBV negative. MA-
GEA4 is expressed in EBV-negative HL, seen only in tumor &
immune-privileged germ cells, and immunogenic. We also observed
that we can increaseMAGE expression by epigenetic modification of
the tumor, supporting our hypothesis.
To verify whether MAGE T cells can be expanded from different
donors, cells from HL patients (n5 4), healthy donors (n5 15) and
cord blood (n 5 4) were stimulated weekly with autologous DCs
pulsed with MAGEA4 peptides. We generated a mixed population
of activated T cells with specificity against MAGE from all donor
types. These cells recognized different MAGE epitopes, and evalu-
able T cells demonstrated specific killing against autologous targets
and HLA-matched HL cell lines.
To explore the effect of combiningMAGET cells with the epige-
netic drug decitabine, we first looked at the effects of adding the drug
to our T cells – to ensure that the drug does not negatively affect
them. We saw no overt effects on or changes in phenotype or spec-
ificity when MAGEA4 T cells were cultured with decitabine. We
then confirmed that treatment of tumors with decitabine in vitro
increased MAGE expression using qPCR.
Lastly, we tested our prediction that increases in the frequency
of MAGEA4 specific T cells would be seen in HL patients receiv-
ing decitabine as therapy. We saw increased MAGEA4 specific T
cells in HL patients following treatment (likely reflecting increased
antigens in vivo) – manifested as an increase in the epitope reper-
toire and in the number of IFNg-secreting cells. We were unable
to expand MAGE T cells in all HL patients treated with decita-
bine, however, highlighting the need for adoptive transfer of these
cells.
These suggest that MAGEA4-specific T cell immunotherapy,
along with epigenetic therapy, is a practical approach for treatment
of relapsed HL post-HSCT.274
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